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Introduction
Chordomas are rare slow-growing low-grade malignant 
tumors of notochordal origin that often have an insidious 
onset.1 They can occur anywhere along the craniospinal 
axis. 32% are intracranial lesions arising extramurally in 
the clivus and midline structures of the skull base, 32.8% 
involve spinal vertebrae, and 29.2% involve the sacrum.1,2 
The annual incidence rate is 0.08 to 0.1 per 100000 
individuals, and the average age at the time of diagnosis 
estimated 60 years. Prognosis is poor with a median 
survival time of 6.29 years and an estimated five-year 
survival rate of just 67.6.3 
The clivus is a bony structure of skull base located 
between the Sella turcica and foramen magnum. Due to 
its proximity to vital structures such as the brain stem, 
basilar artery, internal carotid arteries and cranial nerves 
such as abducens, hypoglossal and vagus nerve treating 
a tumor in this region can be challenging to treat.3 These 
tumors also present challenges concerning diagnosis due 
to their rare prevalence, insidious onset, and tendency to 
involve anywhere throughout the craniospinal axis.1 They 
are also challenging to treat due to their proximity to 
various vital structures and their high rate of recurrence.1,4 
Chordomas can have various presentations. Cranial 
tumors can present with chronic headaches, cranial 
neuropathies, subarachnoid hemorrhage, cerebrospinal 
fluid rhinorrhea, and epistaxis. Spinal tumors can cause 
back pain sphincter dysfunction and paresthesia and 
weakness in lower extremities.1 A multidisciplinary 
approach including neurosurgery, otolaryngology, 
anesthesiology, radiology, oncology, and pathology 
required for successful treatment.3 
Case Report
We report a case of clivus chordoma in a 27-year-old male 
ASA class 1 patient undergoing trans-oral and trans-nasal 
resection of the tumor with a history of trans-nasal tumor 
resection ten months before the surgery and 30 sessions 
of radiotherapy. He presented with headache, dysphagia, 
and dysarthria. On examination he had paresis of right 
cranial nerves, including abducens, glossopharyngeal, 
glossal nerve. The gag reflex was absent. 
Head and Neck Examination
He had adequate mouth opening, normal neck and 
temporomandibular joint movement and a mallampati 
class 1 on oropharyngeal examination.
Lab, Imaging, and Histological Findings
The standard lab test values were within the normal range.
CT scan showed a heterodense area with mass effect 
on medulla and pons. Expansion to nasopharynx with 
prominent involvement of clivus, sphenoid, petrous and 
occipital condyles noted (Figure 1A).
Magnetic resonance imaging showed a heterogenous 
skull base mass with extension to the nasopharynx and 
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bilateral cerebellopontine angles creating the mass effect 
on basilar artery consistent with 9, 10 and 12 cranial 
nerves involvement. (Figure 1B).
Histological results confirmed the diagnosis of 
chordoma.
The patient was scheduled for combined trans-oral 
and trans-nasal debulking surgery with the guide of the 
navigation system under general anesthesia. Due to the 
importance of having a definite airway and holding to 
account the fact that the tumor had a massive protrusion 
in the nasopharynx, we planned for tracheostomy in 
collaboration with otolaryngology department (Figure 
2). The procedure was fully explained to the patient and 
informed written consent obtained.
Pre-induction monitoring included electrocardiogram, 
heart rate, non-invasive blood pressure, and peripheral 
oxygen saturation. 
Before the induction of anesthesia, a lumbar drain 
placed in L4-L5 space.
 Due to the anticipation of difficult intubation 
alternative devices such as video-laryngoscope, Airtraq, 
laryngeal mask airway, tube introducer, and stylet were 
ready in the operating room.
After the premedication with 2 mg midazolam 
for anxiolytics and proper pre-oxygenation, general 
anesthesia induced by administration of 100 mg fentanyl, 
100 mg lidocaine, and 250 mg sodium thiopental. 
Muscle relaxation was achieved using 50 mg atracurium. 
Endotracheal intubation was performed atraumatically 
using a cuffed 8 mm endotracheal tube and correct 
placement of the tube confirmed by capnography. The 
maintenance of anesthesia provided with an infusion of 
10 mg/kg/h of propofol combined with an infusion of 0.1 
µg/kg/min remifentanil.
 Four units of PRBCs were reserved considering the 
proximity of the tumor to the large cranial arteries and the 
possibility of sudden massive hemorrhage, and two units 
of PRBCs were ready for infusion in the operating room. 
We also placed an arterial catheter for monitoring beat to 
beat arterial blood pressure and ease of obtaining blood 
sample throughout the procedure.
Tracheostomy has done in collaboration with the 
otolaryngology department, and the debulking of the 
tumor performed via trans-oral approach followed by 
a trans-nasal approach with the guide of the navigation 
system.
 Phenylephrine mesh was used for optimizing the 
visual field and decreasing the blood loss. Following the 
application of the phenylephrine mesh, the blood pressure 
increased for about 15 minutes, which controlled with an 
additional dose of remifentanil.
The duration of surgery was 6 hours, which was 
uneventful.
Due to the interruption of the bony structure of the 
skull base attempting to place nasogastric tube blindly can 
cause unintentional intracranial tube placement leading 
to the severe neurologic deficit. Therefore, we placed 
the nasogastric tube under vision with the aid of video 
laryngoscope.
The patient was shifted to the neurosurgical ICU and 
was decannulated on the second postoperative day.
Discussion
Chordomas are rare primary malignant locally invasive 
tumors of notochordal origin, which can metastasize to 
other organs.5 They can involve anywhere along with the 
craniospinal structure.
32.8% involve the spine, about 32% occur intracranially, 
and 29.2% involve the sacral bone. The incidence rate is 
0.08 per 100 000, which is higher in the male population, 
0.1 versus 0.06 in the female population.1 Skull base 
chordomas are even more rare with 1 case in 2,000,000 
per year incidence.6 Chordomas represent only 0.1 % of 
tumors in the skull base.7 
The prognosis of these tumors remains poor with a 
median survival time of 6.29 years and a 5-year survival 
rate of just 67.6 %.3
Chordomas can divide into three different 
histopathologic types. Brachyury is a transcription factor 
expressed in all chordomas and is a particular tumor 
marker. It can be used to distinguish chordomas from 
chondrosarcomas, germ cell tumors, and metastatic clear 
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Figure 1. (A) Computed tomography scan shows mass effect on medulla 
and pons with expansion to nasopharynx. (B)Magnetic resonance imaging 
shows skull base mass with protrusion to nasopharynx and mass effect on 
cranial arteries and nerves.
Figure 2. Due to massive protrusion of the tumor to nasopharynx 
tracheostomy was done to ensure a secure airway.
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cell renal carcinomas.1 
Treating chordomas can be challenging due to their 
proximity to various vital structures and their high 
recurrence rate, therefore, en bloc resection may not be 
possible, and microsurgery with the aim of gross total 
resection or subtotal resection followed by adjuvant 
therapy such as radiotherapy is considered to be the 
treatment of choice.1,2,4
Most chordoma patients treated with the trans-
sphenoidal approach.8 However, more extensive 
tumors treated with the transbasal or transpetrosal 
approach.2 Other approaches include trans mandibular, 
transcochlear, transcondylar, subtemporal-preauricular, 
and extreme lateral.1 Chordomas are often resistant to 
conventional radiotherapy.
Imatinib mesylate, a tyrosine kinase inhibitor has been 
successful in tumor liquefaction, shrinking tumor size 
and stabilizing tumor growth while decreasing pain and 
improving life expectancy.1,3 
Managing the resection of clival chordoma has several 
anesthetic considerations. Due to the proximity of the 
tumor to various vital structures, the involvement of 
multiple subspecialties can be helpful.
Several units of packed red blood cells should be ready 
to infuse in the operating room in case of sudden massive 
hemorrhage, and it is optimal to have an arterial line to 
monitor beat to beat arterial blood pressure.
Holding to account the fact that having a definite airway 
is imperative, tracheostomy should be considered in case 
of tumor protrusion to the pharyngeal wall. 
Resecting the clival tumor disrupts the integrity of the 
bony structure of the skull base; therefore, placing the 
nasogastric tube should be under the vision to avoid the 
unintentional intracranial placement.
Phenylephrine is a selective alpha-1 adrenergic agonist. 
It is used in trans-nasal surgery to optimize the visual 
field and minimize blood loss. It can cause episodes 
of hypertension and reflex bradycardia, especially in 
patients with disrupted nasal mucosae due to the history 
of previous surgery. Using phenylephrine mesh should 
be in a careful manner, and symptoms should manage 
accordingly.
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